Board of Directors


Lon R. Hays, M.D., M.B.A.


Dr. Hays graduated from medical school at the University of Kentucky in 1982 then pursued residency training at the University of Kentucky, which he completed in 1986. At that time he joined the faculty in the Department of Psychiatry. In addition to being Board Certified by the American Board of Psychiatry and Neurology, Dr. Hays also is certified in Addiction Medicine, Addiction Psychiatry and Geriatric Psychiatry. He completed a Certificate of Medical Management in 1998 and went on to obtain his M.B.A. from the University of Kentucky Gatton School Of Business in May 2001. Dr. Hays serves as coinvestigator on numerous ROI grants involving cocaine, methamphetamine, opioids, cannabis, and alcohol. Dr. Hays served as Chairman of Psychiatry from 1998-2017. He is the Director of Area V of the American Academy of Addiction and is the current President of the American Board of Addiction Medicine (ABAM) and the American College of Academic Addiction Medicine (ACAAM).

Robert J. Sokol, M.D.

Immediate Past President

Dr. Sokol is Emeritus Distinguished Professor in the Departments of Obstetrics and Gynecology and Physiology and Emeritus Dean of the Wayne State University School of Medicine and Adjunct Professor, in the Department of Epidemiology and Biostatistics of the Michigan State University College of Human Medicine. At Wayne State he served as Chair of the Departments of ObGyn and of Translational Medicine and as Director of the C.S. Mott Center for Human Growth and Development, as well as Senior Vice President for Medical Affairs for the Detroit Medical Center. Among other honors, he was elected President of the Society for Maternal-Fetal Medicine, the Central Association of Obstetricians and Gynecologists, the Detroit Medical Academy and the Wayne State University Academy of Scholars. He chaired the Liaison Committee for Obstetrics and Gynecology and is Editor-in-Chief of ACOG Update, a monthly CME publication. Dr. Sokol has published extensively on the prevention of perinatal brain damage, particularly as it relates to prenatal exposure to alcohol and cocaine. His honors include many national research awards, a lifetime achievement award from the Society of Maternal-Fetal Medicine and awards from the Wayne State University School of Medicine student body, alumni and school. Dr. Sokol has authored almost 1600 publications, including nearly 400 referenced papers. He has served on four boards of directors of professional theaters, one of which he has chaired, three medical school/university boards, one of which he chaired and serves on many other boards and committees.

Martha J. Wunsch, M.D.

President – Elect

Martha J Wunsch, MD, FAAP, DFSAM, is the Medical Director of Addiction Medicine with Kaiser Permanente of Northern California and Director of the Addiction Medicine Consultation-Liaison Service at San Leandro Kaiser Hospital. Dr. Wunsch received her education at the Uniformed Services University of the Health Sciences in Bethesda, MD. Dr. Wunsch works in the CDRP, providing any medical treatment for physically healthy individuals needing addiction treatment. Dr. Wunsch also works with other Kaiser Permanente physicians and NP’s as a teacher to improve understanding and management of patients with substance use problems. Dr. Wunsch is a member of the Sub-Board of Addiction for the American Board of Preventive Medicine. She is also the founding co-editor of the Journal of Addiction Medicine. Other member affiliations include the American Academy of Pediatrics, American Society of Addiction Medicine, and the College on Problems on Drug Dependency.

James M. Vanderploeg, M.D., M.P.H.


Dr. Vanderploeg is an Adjunct Professor of Aerospace Medicine in the Department of Preventive Medicine and Community Health at the University of Texas Medical Branch, Galveston, Texas. He is active in aerospace medical research as a Principal Investigator for the FAA Center of Excellence for Commercial Space Transportation at UTMB. For the past twelve years he has served as the Chief Medical Officer for Virgin Galactic where he is developing the world-wide medical program for Virgin Galactic’s suborbital spaceflight program. He is an Academician and President-elect of the International Academy of Aviation and Space Medicine. His previous leadership activities included President of the Aerospace Medical Association, Board of Directors of the American Board of Medical Specialties, and Trustee and Executive Director of the American Board of Preventive Medicine.

Gail D’Onofrio, M.D., M.S.


Gail D’Onofrio, MD, MS is Professor and Chair of the Department of Emergency Medicine at Yale University and Physician-in Chief of Emergency Services at Yale New Haven Hospital. Boarded in emergency and addiction medicine, she is internationally known for her work in substance use disorders, women’s cardiovascular health, and mentoring physician scientists in developing independent research careers.   For the past 25 years she has developed and tested interventions for alcohol, opioids and other substance use disorders, serving as PI on several large NIH, SAMSHA, and CDC studies that have changed clinical practice. Dr. D’Onofrio has a long track record of mentoring junior and senior faculty members both at Yale and throughout the U.S. in multiple specialties. She is the MPI of a NIDA-funded K12 establishing the Yale Drug use, Addiction and HIV Research Scholars (Yale-DAHRS) program, a three-year post-doctoral, interdisciplinary, Mentored Career Development Program with focused training in prevention and treatment of drug use, addiction, and HIV in general medical settings.  She has received multiple clinical, leadership and mentorship awards including the Excellence in Mentoring award from the Association for Medical Education and Research in Substance Abuse (2008), Advancing Women in Emergency Medicine award (2016) and the Department of Emergency Medicine Advancement of Women Award (2018) from the Society of Academic Emergency Medicine. She is a founding Board member of Addiction Medicine, now recognized as a new specialty, subspecialty by the American Board of Medical Specialties. An advocate for individuals with opioid use disorder, she is one of the architects of Connecticut Governor’s Strategic Plan to Reduce Opioid Deaths, working with multiple agencies regionally and nationally to change policies and introduce interventions to combat the opioid crisis.


Hoover Adger, Jr., M.D., M.P.H.

Dr. Adger is Professor of Pediatrics at the Johns Hopkins University School of Medicine and Director of Adolescent Medicine at the Johns Hopkins Hospital, which he joined in 1984. Since that time, he has served as Director of the Substance Abuse Assessment/Intervention Team at The Johns Hopkins Hospital Adolescent Program and as Director of The Johns Hopkins Substance Abuse Faculty Development Programs. In February 1997, Dr. Adger was selected to fill the position of Deputy Director of the White House Office of National Drug Control Policy. In July 1998, he returned to Johns Hopkins to resume his duties as a full-time faculty member. From 1999-2005, he served as Co-Director of the Strategic Planning Initiative funded by HRSA and SAMHSA/CSAT to advise the federal government and others on improving and expanding interdisciplinary education and training of health professionals in substance use disorders. He currently serves as principal investigator and project director of the HRSA-funded Leadership & Education in Adolescent Health project at the Johns Hopkins Hospital and as the faculty leader of the Florence Sabin College in the Johns Hopkins School of Medicine. Dr. Adger also is a past president of the Association for Medical Education and Research in Substance Abuse and a past president of the National Association for Children of Alcoholics.

Louis E. Baxter, M.D.

Dr. Baxter is the President and CEO of the Professional Assistance Program of New Jersey that manages impaired healthcare professionals. He is also the Medical Director for the Division of Addiction Services in the State of New Jersey Department of Human Services, Associate Clinical Professor of Medicine at Rutgers Medical School (formally UMD NJ), and serves as Co-Program Director of Howard University Medical Center’s addiction medicine fellowship.  Dr. Baxter completed his undergraduate degrees in Biology and American Civilization at the University of Pennsylvania and earned his Medical Doctorate at Temple University School of Medicine. Dr. Baxter completed his Internship and residency training in Internal Medicine at UMDNJ Cooper Hospital University Medical Center. He sub-specialized in Addiction Medicine through training at Portsmouth Psychiatric Hospital. Dr. Baxter is an Associate Clinical Professor of Medicine at the University of Medicine & Dentistry New Jersey in Newark New Jersey. He is Immediate Past President of the American Society of Addiction Medicine and serves on the Board of Directors. He has also been appointed to the Board of Directors of the National Association of Drug Court Professionals. He has served on a number of National Advisory Councils and Committees which include, SAMSHA, CSAT, NIDA, NIAAA and the FDA. He is a member of many other medical organizations and has many publications.

Tim Brennan

Tim Brennan, M.D., M.P.H.

Vice President for Medical and Academic Affairs

Phone: 301-656-3880 x392


Dr. Brennan is the Vice President for Medical and Academic Affairs at the American College of Academic Addiction Medicine. He is passionate about expanding high-quality and financially sustainable academic addiction medicine fellowship training around the United States. Dr. Brennan works with emerging and established fellowship programs from inception to accreditation. Additionally, he is the Director of the Addiction Institute at Mount Sinai West and Mount Sinai St. Luke’s Hospitals and the Program Director of the Fellowship in Addiction Medicine Program at the Icahn School of Medicine Mount Sinai in New York City. Dr. Brennan has spoken at state, national and international levels about addiction policy issues, particularly as related to young adults. He is the co-editor of Lippincott’s “Essentials of Addiction Medicine”, and was appointed by Governor Cuomo to serve on the Medical Review Board at the New York State Justice Center.

Dr. Brennan is Board Certified in Pediatrics by the American Board of Pediatrics and Board Certified in Addiction Medicine by the American Board of Preventive Medicine.

Randall Brown

Randall Brown, M.D., Ph.D.

Dr. Brown is an Associate Professor at The University of Wisconsin Department of Family Medicine and Community Health. Dr. Brown’s primary interests revolve around the treatment and prevention of substance use disorders and their complications in settings outside of the specialist treatment environment (such as primary care, hospitals, pharmacies, and criminal justice settings). He is Board Certified in Family Medicine and in Addiction Medicine. Dr. Brown came to Madison in 2001 to participate in the NIH/NRSA Primary Care Research Fellowship, with focus on addiction health services research, and he attained a PhD in UW’s Dept of Population Health Sciences in 2009. His current research includes investigations in opioid misuse prevention, mobile technology to support recovery, promotion of medication prescribing for alcohol use disorders in primary care, and potential therapeutic applications of psilocybin and MDMA. He serves as a consulting physician in addiction medicine at 2 Madison hospitals, the UW HIV Clinic, and at Access Community Health Centers. Dr. Brown is also the Founding Director of the UW Addiction Medicine Fellowship Program, the Director of the UW fourth year Clinical Addiction Elective, and the Medical Director of the Overdose Prevention Program of the AIDS Resource Center of Wisconsin.

Randall Brown

Anna Lembke, M.D.

Anna Lembke, MD, is an associate professor in the Department of Psychiatry and Behavioral Sciences at Stanford University School of Medicine. She is medical director of Stanford Addiction Medicine, program director for the Stanford Addiction Medicine Fellowship, and chief of the Stanford Addiction Medicine Dual Diagnosis Clinic. Dr. Lembke received her BA in Humanities from Yale University and her MD from Stanford University, where she also completed her residency in Psychiatry and fellowship in mood disorders. She is a diplomate of the American Board of Psychiatry and Neurology, and of the American Board of Addiction Medicine. Dr. Lembke has developed multiple teaching programs on drug misuse and addiction therapy. She has held multiple leadership and mentorship positions and received the Stanford’s Chairman’s Award for Clinical Innovation, and the Stanford Departmental Award for Outstanding Teaching. She chaired the Planning Committee for the California Society of Addiction Medicine (CSAM) Annual Addiction Medicine Conference and was the president of the Addiction Medicine Fellowship Directors Association (AMFDA). She is the author of the bestselling book, “Drug Dealer, MD: How Doctors Were Duped, Patients Got Hooked, and Why It’s So Hard to Stop” (Johns Hopkins University Press, November 2016).

Randall Brown

Sharon Levy, M.D., M.P.H.

Sharon Levy, MD, MPH is a Developmental-Behavioral Pediatrician, Addiction Medicine specialist and Associate Professor at Harvard Medical School. She is the Director of the Adolescent Substance Use and Addiction Program at Boston Children’s Hospital, the past chair of the American Academy of Pediatrics Committee on Substance Use and Prevention, the President of the Association for Medical Education and Research in Substance Abuse and she serves on the board of directors of the Addiction Medicine Fellowship Director’s Association. Over the past 20 years she has evaluated and treated thousands of adolescents with substance use disorders, and she has written extensively on the topic. In 2016 she established the nation’s first accredited Pediatric Addiction Medicine Fellowship training program at Boston Children’s Hospital. She has conducted research to develop and test tools for identifying and addressing adolescent substance use disorders in general medical settings, and she has expertise in the integration of substance use treatment services into pediatric primary care.

Randall Brown

Paula J. Lum, M.D., M.P.H.

Dr. Lum is a Professor of Clinical Medicine at the University of California, San Francisco (UCSF). She is the Program Director of the UCSF Primary Care Addiction Medicine Fellowship, a one-year ACGME-accredited clinical training program that combines the resources of the UCSF School of Medicine and the San Francisco Department of Public Health to prepare primary care physicians to become leaders in the care of persons with unhealthy substance use in San Francisco’s safety net communities.

Board certified in internal medicine and addiction medicine, Dr. Lum practices and teaches primary care at the places where HIV, addiction, and poverty collide. Her research and clinical activities are grounded in evidence-based, patient-centered care that improves the health outcomes and life quality of the urban poor. Dr. Lum’s academic interests include: (1) HIV and viral hepatitis prevention and treatment in persons who inject drugs, (2) innovations to address unhealthy substance use and its complications in primary care and non-traditional settings, and (3) curricular interventions to provide health care professionals with the skills, knowledge, and confidence to offer compassionate and effective care to persons who use drugs. Her work has been funded by the NIH/NIDA, HRSA, SAMHSA, and PCORI.

Dr. Lum was born in Honolulu, Hawaii. She attended Stanford University where she studied Human Biology (A.B.) and Sociology (A.M.), and earned her medical degree from Case Western Reserve University in Cleveland, Ohio as a National Health Service Corps Scholar. She completed her internship and residency at the UCSF Primary Care Internal Medicine Residency Program at San Francisco General Hospital (SFGH) and a NRSA-funded post-doctoral fellowship at the UCSF Center for AIDS Prevention Studies. During this time, she earned a Master in Public Health from the University of California, Berkeley. In 1999, Dr. Lum joined the faculty of the UCSF HIV/AIDS Division at SFGH, where she still works today.

Michael M. Miller, M.D.

Michael M Miller, MD, DLFAPA, DFASAM, is a board-certified general and addiction psychiatrist and is certified in Addiction Medicine by the American Board of Preventive Medicine. A Distinguished Life Fellow of the American Psychiatric Association and a Distinguished Fellow of the American Society of Addiction Medicine (ASAM), Dr. Miller is also a director of the American Board of Addiction Medicine (ABAM) and the American College of Academic Addiction Medicine (ACAAM).

Dr. Miller completed the fellowship program in addiction medicine and addiction psychiatry at the University of Minnesota in 1983, then founded and served 5.5 years as the Medical Director of the Eau Claire (WI) Regional Detoxification Center at Luther Hospital.  He then served 21.5 years as Medical Director of the NewStart Alcohol/Drug Treatment Program in Madison, WI, which included an active detox admission service and consultation service, and which served as a training site in addiction evaluation and withdrawal management for medical students, residents, and Addiction Medicine fellows from the University of Wisconsin. After 8 years as medical director of the Herrington Recovery Center, a residential treatment program for adults at Rogers Memorial Hospital which integrates mental health and addiction care in a national-calibre Dual Diagnosis program, he joined the core faculty of the UW-Madison providing clinical teaching for fellows in Addiction Medicine and Addiction Psychiatry.  He has decades of experience in Physician Health, consults to the Wisconsin Lawyers Assistance Program, and has a private practice in Madison focusing on the treatment of licensed professionals with addiction.

Dr. Miller served as ASAM’s President and Board Chair for 2007-09 and  received the ASAM Annual Award in 2013.  On April 5, 2019, he was bestowed ASAM’s highest honor, its John P. McGovern Award.

Patrick G. O’Connor, M.D., M.P.H.

Dr. O’Connor is the Dan Adams and Amanda Adams Professor and Chief of General Internal Medicine at Yale University School of Medicine and Yale-New Haven Hospital in New Haven, Connecticut. Dr. O’Connor’s research and scholarly work have focused on the interface between primary care and substance abuse. He has written well over 200 papers on these topics that have been published in leading medical journals including The New England Journal of Medicine and JAMA. Dr. O’Connor’s work in the area of opiate detoxification led to research examining the efficacy of opioid maintenance therapy for treating opioid use disorder in primary care and other general medical settings. He and his colleagues at Yale completed a series of studies that look at the effectiveness of methadone and of buprenorphine as the pharmacological agent for this treatment in primary care and emergency medicine settings. Among his accomplishments as Chief of General Internal Medicine at Yale is the recruitment of several academic “generalist” faculty to join efforts to perform research on a broad range of topics related to addiction medicine. The overall goal of this research is to improve access to treatment for patients with substance use disorders to high quality care for their substance use disorders in the context of their general medical care.  Dr. O’Connor is also Past President of both The American Board of Addiction Medicine (ABAM) and AMERSA.


Jeffrey H. Samet, M.D., M.A., M.P.H.

Dr. Samet is a graduate of Brandeis University and Baylor College of Medicine. He trained in Internal Medicine including chief residency at Boston City Hospital, Boston University School of Medicine (BUSM), and in a research fellowship at the Massachusetts General Hospital. He has been a primary care physician in Boston since 1983. Dr. Samet is the John Noble Professor of General Internal Medicine at BUSM and Professor of Community Health Sciences at the Boston University School of Public Health. He has been Chief of General Internal Medicine at BUSM/Boston Medical Center since 2002. Dr. Samet has a longstanding commitment to educating physicians about substance use disorders leading NIDA R-25 programs funding the Research in Addiction Medicine Scholars (RAMS) Program and the Chief Resident Immersion Training (CRIT) Program in addiction medicine. He was President of AMERSA (1999- 2001), a member of the Institute of Medicine Committee on “Addressing the Quality Chasm in Mental Health and Addictive Disorders” (2004-2006) and President of the American Board of Addiction Medicine (2012-13). His research interests addressing HIV and substance use and the integration of addiction treatment into mainstream medical care have been supported by NIDA and NIAAA for over 2 decades.


Jeanette M. Tetrault, MD FACP FASAM

Dr. Tetrault is a graduate of Boston University School of Medicine and trained in Internal Medicine/Primary Care at Yale School of Medicine. She is currently an Associate Professor of Medicine in the Section of General Internal Medicine at Yale University School of Medicine. She is the Program Director for the Yale’s Addiction Medicine Fellowship and the co-director of the Addiction Recovery Clinic at Yale New Haven Hospital St. Rapheal’s Campus Adult Primary Care Center, which is an addiction treatment clinic and residency training site embedded within the academic primary care practice. For the past 10 years, Dr. Tetrault has served as the Internal Medicine Team Leader for the Substance Abuse and Mental Health Services Administration-funded Screening, Brief Intervention and Referral to Treatment (SBIRT) initiative at Yale School of Medicine. In addition to being a director for the Addiction Medicine Foundation, she is also on the Board of Directors of the Addiction Medicine Fellowship Director’s Association. She serves as co-chair of the Society of General Internal Medicine’s (SGIM) Alcohol, Tobacco and Other Drug Use Interest Group, is a past- president for the New England Region of SGIM. Dr. Tetrault was recently recognized as a Macy Foundation Faculty scholar for her work in addiction medicine curriculum development for interprofessional students. Her academic interest focuses on improving care of patients with substance use and the chronic diseases associated with addiction. Her work focuses on epidemiologic investigation, investigation of unique delivery care models, examination of safety of addiction pharmocotherapies, and addiction medicine curriculum design, evaluation, and dissemination.


Scott Teitelbaum, M.D.

Scott Teitelbaum, M.D., is the Pottash Professor in Psychiatry and Neuroscience at the University of Florida’s College of Medicine, where he serves as Vice Chair of the Department of Psychiatry, Chief of the Division of Addiction Medicine, Medical Director of the UF Health Florida Recovery Center, and Fellowship Director of UF’s American Board of Preventative Medicine (ABPM) – Addiction fellowship.
Originally trained and board-certified as a pediatrician, Dr. Teitelbaum later completed fellowships in addiction medicine and child psychiatry at the University of Florida. Dr. Teitelbaum became medical director of the Florida Recovery Center in 2002, and since then has evaluated and treated more than 3,000 healthcare providers and other professionals from across the country. Through his efforts, the Florida Recovery Center has led the way nationally with its evidence-based treatment of the disease of addiction.

Dr. Teitelbaum developed one of the first-ever accredited fellowships in addiction medicine. His program now has trained more addiction-medicine fellows than any other program nationwide. In 2016, Dr. Teitelbaum was awarded the Pottash Endowment, allowing for the creation of a research initiative that’s focused on addiction medicine and the fight toward recovery. He has been honored with the Exemplary Teacher Award for his guidance of medical students.

In January 2018, the American Society of Addiction Medicine named Dr. Teitelbaum winner of its Prestigious Annual Award, in recognition of his outstanding contributions to the field.
A national expert who has been consulted by the White House Office of National Drug Control and the U.S. Drug Enforcement Administration, Dr. Teitelbaum is passionate about reducing stigma and advancing treatment for those suffering from the disease of addiction.


Alexander Y. Walley, M.D., M.Sc.

Dr. Walley is an Associate Professor of Medicine at Boston University School of Medicine and a general internist and addiction medicine specialist at Boston Medical Center. He has been the director of the Boston Medical Center Addiction Medicine Fellowship program since 2011. His research focus is on the medical complications of substance use, specifically HIV and overdose. He provides primary care and office-based addiction treatment for patients with HIV at Boston Medical Center and on the inpatient Addiction Consult Service, which he founded in 2015. He is the medical director for the Massachusetts Department of Public Health’s Opioid Overdose Prevention Pilot Program. Since 2007, the MDPH program has trained over 80,000 people in Massachusetts’s communities, including people who use opioids, people in recovery, and their social networks. He graduated from Harvard College, received his MD from Johns Hopkins School of Medicine and Masters of Science in epidemiology from Boston University School of Public Health.